Ocaratuzumab (AME-133v, LY2469298) is a humanized monoclonal antibody designed for the treatment of cancer and autoimmune disorders. The antibody is engineered...
5 KB (489 words) - 06:58, 17 November 2023
Obinutuzumab Gazyva mab humanized CD20 Y chronic lymphatic leukemia Ocaratuzumab mab humanized CD20 cancer Ocrelizumab Ocrevus mab humanized CD20 Y multiple...
135 KB (4,013 words) - 12:02, 22 May 2024
trials in 2008) include : Obinutuzumab for systemic lupus erythematosus, Ocaratuzumab for follicular lymphoma and rheumatoid arthritis, TRU-015 (by Trubion)...
26 KB (2,953 words) - 12:22, 29 May 2024
Lumretuzumab§ Matuzumab§ Milatuzumab§ Naxitamab Nimotuzumab† Obinutuzumab Ocaratuzumab§ Otlertuzumab§ Onartuzumab§ Oportuzumab monatox† Parsatuzumab§ Pertuzumab...
4 KB (241 words) - 11:41, 22 April 2022
Lumretuzumab§ Matuzumab§ Milatuzumab§ Naxitamab Nimotuzumab† Obinutuzumab Ocaratuzumab§ Otlertuzumab§ Onartuzumab§ Oportuzumab monatox† Parsatuzumab§ Pertuzumab...
5 KB (368 words) - 22:00, 19 October 2020
Lumretuzumab§ Matuzumab§ Milatuzumab§ Naxitamab Nimotuzumab† Obinutuzumab Ocaratuzumab§ Otlertuzumab§ Onartuzumab§ Oportuzumab monatox† Parsatuzumab§ Pertuzumab...
3 KB (129 words) - 01:04, 19 July 2023